Kornimate/medical-research-clean huggingface dataset:
the effects of elliptical cross training bike for stroke patients

Conditions: Stroke

Summary: to investigate the effects of elliptical cross bike exercises combine conventional physical therapy on gait, postural control, balance, muscle tone, spasticity, quality of life, motor functioning, functional activity, and adl in post stroke patients.

in a single-blind, randomized controlled intervention, patients were randomly assigned to an active cycling group (acg, n=25) five times a week combine with conventional al physical therapy or a control group (cg, n=25) with conventional physical therapy 3 weeks of training in the center. all outcome measures were administered at the beginning of the study, at the end of the 1st, 2nd, and 3rd week. all participants will be divided two groups. one group will be experiment with conventional physical therapy as control group (cg), the other group will active cycling as active cycling group (acg) with elliptical cross trainer \& exercise bike after conventional physical therapy. baseline assessment of muscle tone by myoton-3, modified ashworth scale used as a simple measure of spasticity; barthel index scale for performance in activities of daily living; berg balance scale to measure balance; the upper and lower limb subscale of the fugl-meyer assessment for motor function of extremities; and bts g-walk was used to measure gait parameters. the data will be collect before session.

Eligibility criteria:
inclusion criteria: * first-ever stroke (world health organization ,1978). * joint mobility ranges of lower extremity that would not preclude pedaling(ambrosini, ferrante et al. 2011). * unilateral hemiplegia. * able to carry out simple instructions. * able to sit independent at least 20 minutes and pedal an elliptical cross bike. exclusion criteria: * neurologic disorders with impaired functionality existing pre-stroke. * patients could not follow instructions. * cardiovascular disease or other risk factor which precluded participation in aerobic exercise. * peripheral neuropathy that could potentially interfere with this study.

Keywords: post stroke gait elliptical cross bike. postural control balance
the experience of older adults facing depression for the first time in old age

Conditions: MAjor Depressive Disorder

Summary: analysis of recent studies show that researchers find it hard to distinguish between late onset depression, a first diagnosed major depressive episode which occurs at old age, and early onset depression, a depressive episode at old age with a history of previous episodes. since current data, about the phenomenology and etiology of late onset depression, lake conicity it is unclear whether this phenomena should be considered as a distinct subtype of depression. nevertheless, the wide spread assumption is that late onset depression has a stronger correlation with brain damage and environmental risk factors such as the common losses at old age and weaker correlation with family history and genetics when compared to early onset. although many researchers consider brain damage to have the main contribution to the emerge of late onset depression, the fact that depression has a negative effect on one's health supports the claim that it might be the result and not the rick factor. since late onset depression correlates with the common losses at old age, the investigators propose that an existential approach that deals with one's meaning, freedom, responsibly and death, might be more appropriate. thus, the investigators ask how do older adults experience depression which they face for the first time in old age? current study will seek to understand older adults' experience of late onset depression through existential paradigm by using a semi constructed interview.


Eligibility criteria:
inclusion criteria: 1. men aged 67 or more, women aged 62 or more 2. diagnosis of major depressive disorder, minor depressive disorder or adjustment disorder with depressive features made after the age of 67 with men and 62 with women. 3. basic understanding and ability to converse in hebrew. exclusion criteria: 1. history of at least one previous major depressive or minor depressive episode before the age of 62 with women or 67 with men 2. mental retardation or autistic spectrum disorder 3. significant cognitive impairment observed by the primary physician. 4. schizophrenia or schizoaffective disorder. 5. depressive episode with psychotic features 6. substantial suicidality
impact of intraoperative icg on functional outc in rarp

Conditions: Prostate Adenocarcinoma

Summary: this is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (icg) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function outcomes at 12 months postoperatively.

the first phase of this study will involve performing 50 cases of nerve-sparing rarp on patients who are good candidates for nerve sparing. during these procedures, we will record the location and size of arteries encountered to create a detailed 3d map of the surgical arterial vasculature. in the second phase, we will recruit another 50 patients. these patients will receive an iv injection of icg before encountering the arteries to visualize them prior to resection. this phase will determine the optimal dosage and timing for the iv icg injection. the third phase will utilize the dosage and timing defined in the second phase. this phase will be a randomized trial involving 300 patients.

Eligibility criteria:
inclusion criteria: * 1. subjects must be ≥18 years old, male, and sexually active. * 2. histologically/pathologically confirmed localized prostate adenocarcinoma. * 3. most recent preoperative sexual health inventory for men (shim) score ≥16. * 4. subjects who are candidates for good nerve sparing preoperatively determined by the investigator by assessing imaging findings. * 5. ability to read, write and understand and willingness to sign a written informed consent. * 6. subjects must pass medical clearance from primary care provider and cardiologist, if applicable. * 7. subject must be determined to be medical fit for rarp by the investigator. exclusion criteria: * 1. no locally advanced or metastatic prostate adenocarcinoma. * 2. preoperative diagnosis of erectile dysfunction with any use of invasive interventions such as intrapenile injections and intrapenile prosthesis implants. oral interventions are acceptable and are not exclusionary. * 3. received neoadjuvant treatment for high-risk prostate cancer or received prior focal treatment of the prostate or prior definitive radiotherapy. * 4. history of allergic reactions attributed to icg. * 5. subjects who are preoperatively not foreseen as ideal candidates for nerve sparing interventions by the investigator. * 6. subjects who are unable to comply with study and follow-up procedures as judged by the investigator. * 7. subjects who are illiterate. * 8. other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, or uncontrolled diabetes. * 9. any other disease, metabolic disorder, or abnormal finding upon physical examination or laboratory examination that makes the subject unsuitable for receiving the intervention, affects the interpretation of study outcomes, or poses risks to subject safety, as determined by the investigator.
effectiveness of a bonding and a fluoride varnish for long-term dentin hypersensitivity treatment.

Conditions: To Decrease Dentin Hypersensitivity

Summary: objectives: the aim of this in vivo randomized clinical trial with split-mouth design was to evaluate the clinical efficacy of one in-office application of a fluoride containing varnish and in office application of a bonding resin in adult patients presenting with dentin hypersensitivity. materials and methods: the study cohort consisted of 38 caucasian outpatients, giving a total of 180 teeth were treated by fluoride varnish (fv) and 160 - by bonding agent (ba). baseline pain in fv group was slightly higher on both scales (schiff and vas). outcome measurements were assessed one or two weeks before product application (enrollment), at baseline at the application days (end of the run-in period: t0a, t0b, t0c), and at 1 week and at 1-2-6 months after first treatment.


Eligibility criteria:
inclusion criteria: * absence of systemic pathologies (asa class i); * not pregnant or lactating; * good oral hygiene; * with ≥1 sensitive tooth with exposed dentin on upper or lower dental arches; * contemporary presence of exposed dentin both on the left and right counterpart of upper or lower arch. exclusion criteria: * domestic or in-office professional fluoride application and bleaching 6 months before beginning of treatment; * long-term use of anti-inflammatory, analgesic and psychotropic drugs; * eating disorders, systemic conditions that cause or predispose patients to develop dentin hypersensitivity (for example, gastroesophageal reflux disease); * periodontal surgery and within the previous three months before the study; * orthodontic treatment within the previous three months before the study.

Keywords: dentin hypersensitivity bonding agent fluoride varnish
study of the efficacy and safety of lonidamine for the treatment of symptomatic benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia; Enlarged Prostate

Summary: the purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic bph.


Eligibility criteria:
inclusion criteria: * capable of understanding the purpose and risks of the study and sign a statement of informed consent * male 50-80 years of age * presence of luts (lower urinary tract symptoms) for at least 3 months * prostate volume measured by trus (transrectal ultrasound) \> 30 cc * qmax \< 15 ml/sec when measured by uroflowmetry (minimum of 125 ml must be voided) * i-pss (international prostate symptom score) \> 12 * psa \> 1.0 ng/ml * must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential * able to comply with the prescribed treatment protocol and evaluations exclusion criteria: * prior treatment for bph with alpha-blockers and/or herbal supplements in the past 2 weeks (alpha-blockers and herbal supplements for the treatment of bph are not allowed during the study). prior treatment with 5-alpha-reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment. * prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.) * current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (for subjects with psa between 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the principal investigator. subjects with psa \>10 ng/ml are excluded.) * active urinary tract infections (uti) * active cardiac, renal or hepatic disease as evidenced by: 1. serum creatinine \> 1.8 mg/dl 2. alt or ast \> 2.5x the upper limit of normal at screen 3. history of active myocardial infarction,unstable cardiac arrhythmias or stroke within 6 months prior to screening 4. uncontrolled congestive heart failure * uncontrolled diabetes mellitus (fasting blood glucose \> 200 mg/dl) * use of systemic teriods for any reason (systemic steroid usage is not allowed during the study). inhaled and/or topical steroids are allowed. * concurrent participation or participation in an investigational drug study within the past 30 days prior to screening * concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the investigator,pose an unnaceptabele risk to the subject

Keywords: benign prostatic hyperplasia bph enlarged prostate
targeting mitochondrial fusion and fission to prevent atherosclerosis: getting the balance right

Conditions: CAD Patients

Summary: our preliminary data suggests that pharmacological inhibition of the mitochondrial fission protein, drp1, reduced atherosclerotic plaque volume and attenuated macrophage accumulation within the plaque in an apoe-/- mouse model of wire-induced carotid arterial injury. furthermore, we hypothesize that modulation of mitochondrial morphology and metabolism with drp1 inhibition prevents atherosclerosis by reducing monocyte activation and migration. in this research proposal, our overall objective will be to investigate the role of drp1 in human monocytes and macrophages as novel therapeutic targets for preventing atherosclerosis.

study 1 (tissue sample study): to investigate the changes in mitochondrial function and pro-inflammatory markers in human arterial atherosclerotic plaques. hypothesis: macrophages from femoral artery atherosclerotic plaques in patients with peripheral artery disease will display upregulation of mitochondrial fission proteins and features of pro-inflammatory activation. study 2 (white blood cell study): to investigate the changes in mitochondrial function and pro-inflammatory markers in white blood cells from patients with stable and unstable coronary artery didease (cad). hypothesis: monocytes from patients with unstable cad will display upregulation of drp1 and features of pro-inflammatory activation, mitochondrial fission, impaired mitochondrial respiratory function, and perturbed metabolism, when compared to monocytes from patients with stable cad.

Eligibility criteria:
inclusion criteria: study 1 (tissue sample study): cabg patients 1. patients aged ≥21 years old 2. undergoing elective cabg with aortic valve surgery pad patients: 1. patients aged ≥21 years old 2. undergoing either elective surgical femoral or carotid endarterectomy study 2 (white blood cell study): 1) healthy volunteers aged ≥21 years old 2) patients with stable cad 3) patients admitted with acs treated by pci in prior 24 hours. - exclusion criteria: 1. general exclusion criteria will be a known history of leucopenia, thrombocytopenia, or severe hepatic or renal dysfunction, as well as evidence for inflammatory or malignant disease. 2. history of haematological disorders 3. cardiac arrest, cardiogenic shock, poor pre-morbid status, pregnancy
evaluation of mcm5 in postmenopausal bleeding patients

Conditions: Endometrial Cancer

Summary: the objective of this multi-centre, prospective study, is to evaluate the performance of a urine mcm5 elisa test (adxgynae) in the detection of endometrial cancer in patients with postmenopausal bleeding. patients attending a gynaecology clinic for investigation of postmenopausal bleeding will be recruited and asked to provide a urine sample to be tested. the results of the mcm5 test will be recorded and compared to the patient's routine investigations to determine the clinical utility of the test as an aid in the diagnosis of endometrial cancer.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * patients who are at least 1 year post-menopausal i.e. have not had a menstrual period for at least one year * patients who, in the opinion of the investigator, are suitable for standard gynaecological investigations as part of normal clinical practice * patients who are, in the opinion of the investigator, able to understand the purpose of the study and provide a full void urine specimen * patients who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained exclusion criteria: * patients with known symptomatic calculi within the urino-genitary system * patients currently undergoing chemotherapy or radiotherapy * patients who have previously been diagnosed with bladder or renal cancer who are currently in follow up * patients with a medical contraindication to endometrial biopsy * patients who do not wish to have an endometrial biopsy even if deemed necessary by the treating physician * patients who have had urological instrumentation to the urinary tract within 14 days prior to the test (including catheterisation) * patients who have had any gynaecological instrumentation in the previous 14 days

Keywords: endometrial cancer postmenopausal bleeding mcm5 biomarker
the effect and mechanism of transcutaneous auricular vagus nerve stimulation on gait impairments in pd

Conditions: Parkinson Disease

Summary: this study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on parkinson's disease patients . we hypothesize that treatment using transcutaneous auricular vagus nerve stimulation will improve gait impairments and cortical activity in parkinson's disease patients.

patients in the experimental group underwent seven consecutive daily sessions of transcutaneous auricular vagus nerve stimulation (tavns, twice daily, 30 minutes each time) , whereas patients in the sham stimulation group underwent seven consecutive daily sessions of sham tavns. assessments of gait function, motor symptoms and cortical activity (using functional near-infrared spectroscopy) were performed two times: at baseline, one day post intervention.

Eligibility criteria:
inclusion criteria: 1. idiopathic parkinson's disease (pd), as diagnosed by a neurologist. 2. hoehn and yahr stage ≤ 2 during on medication state. 3. age between 40 and 80 years old. 4. mini-mental state examination score \>24. 5. ability to walk at least 60s independently. 6. stable medication exclusion criteria: 1. patients with significant visual impairment or coexisting local or systemic diseases (e.g. osteoarthritis or other neurological conditions) likely to affect gait were excluded from our study. 2. patients who underwent deep brain stimulation surgery or those with an implanted cardiac pacemaker were also excluded 3. patients with known or suspected cardiovas-cular disease, uncontrolled hypertension or recent myocardial infarction were also excluded from the study.

Keywords: gait therapeutics
patient registry study of berinert® in normal clinical practice

Conditions: Includes: Hereditary Angioedema

Summary: the objective of this patient registry is to collect data on the safety of berinert® in normal clinical practice in the united states. the patient registry will be maintained for a period of at least 3 years. the duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (hae) attacks and the patient's need for berinert® treatment.


Eligibility criteria:
inclusion criteria: * any patient receiving csl behring's c1-esterase inhibitor * written informed consent (may not be required for some retrospective chart review cases) exclusion criteria: * any patient participating in an hae study using other c1-inhibitors than berinert®

Keywords: c1-esterase inhibitor hereditary angioedema acute hae attack
brain imaging of psychotherapy for posttraumatic stress disorder (ptsd)

Conditions: Posttraumatic Stress Disorder (PTSD)

Summary: the investigators are seeking people who have been exposed to a traumatic event in the past and have symptoms of posttraumatic stress disorder (ptsd) currently. a person with ptsd may feel significant distress when reminded of a traumatic event or feel depressed, anxious or jumpy. as a part of this study, participants will receive brain mris and office assessments before and after psychotherapy. the investigators provide the gold-standard psychotherapy for ptsd, "prolonged exposure", free of charge; additionally participants are compensated for their time during assessment procedures. this study is exploring the brain circuitry involved in improvement in response to psychotherapy.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 60 years; 2. fmri scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce artifacts when brain imaging; 3. not currently involved in an exposure-based psychotherapy, in order to be able to measure and interpret the effects of pe on ptsd; 4. must comprehend english well and show non-impaired intellectual abilities to ensure adequate comprehension of the fmri task instructions and pe treatment; 5. no history of neurological or cardiovascular disorders, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, diabetes, hypo- or hyperthyroidism, head trauma with loss of consciousness greater than thirty minutes; 6. no regular use of benzodiazepine, opiate, thyroid, anticonvulsant or antipsychotic medications. patients on stable doses of antidepressant medications will be allowed. patients for whom antidepressant dosing is being actively titrated will be required to be on a stable dose for 1 month prior to inclusion in the study. exclusion criteria: * any contraindication to being scanned in the 3t or 1.5t scanners at the lucas center or cni such as having a pacemaker or implanted device that has not been cleared for scanning at the lucas center or cni. * participants will be excluded from the study if there is any lifetime evidence of psychosis, mania, hypomania, or bipolar disorders. other axis i comorbidities will not be a cause for exclusion. in addition, subjects will be excluded if they have a significant cns neurological condition such as stroke, seizure, tumor, hemorrhage, multiple sclerosis, etc. patients who have current substance dependence will be excluded from the study. a recent diagnosis of substance abuse is allowable, however, as long as subjects have been abstinent for greater than three months. * subjects will be excluded if they are currently in an exposure-based psychotherapy for ptsd.

Keywords: posttraumatic stress disorder (ptsd) psychotherapy non-medication treatment prolonged exposure transcranial magnetic stimulation (tms) anxiety disorders emotion emotion regulation functional mri affective symptoms
emervel classic lidocaine versus juvederm® ultra in treatment of moderate to severe facial wrinkles and folds

Conditions: Skin Wrinkling

Summary: the purpose of this study is to compare the effectiveness and safety of emervel classic lidocaine versus juvederm® ultra in the treatment of moderate to severe facial wrinkles and folds.


Eligibility criteria:
inclusion criteria: * the subject is a male or female 18 years of age or older * the subject has bilateral nasolabial folds that, in the opinion of both the blinded evaluating investigator and the unblinded injecting investigator, can be corrected with an injectable dermal implant * the subject has the same wrinkle severity rating scale (wsrs) score of 3 or 4 (moderate or severe) for each nasolabial fold exclusion criteria: * the subject has active skin disease or inflammation on or near a nasolabial fold that, in the principal investigator's opinion, would interfere with the study device injections and/or study assessments. * the subject has a history of sensitivity to hyaluronic acid * the subject has a history of sensitivity to lidocaine or other amide type anesthetics * the subject is, in the principal investigator's opinion, at undue risk based on the precautions, warnings and contraindications for local lidocaine anesthetics.